GlassScriptPhysician profile
Kenneth F Khandagle
NPI 1508849274
$4,151.09
in general payments reported to CMS, 2019-2025
33 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $266 · 2021: $13.00 · 2022: $26.27 · 2023: $409 · 2024: $1,237 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $690.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $690.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $529.09 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.75 | 2019-2025 | Jardiance |
| Abbvie INC. | $245.61 | 2019-2025 | |
| Astellas Pharma US INC | $232.79 | 2019 | |
| Pfizer INC. | $211.93 | 2019-2025 | |
| Amgen INC. | $206.49 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $103.75 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $101.02 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $89.54 | 2020-2024 | |
| Glaxosmithkline, LLC. | $78.52 | 2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Kowa Pharmaceuticals America, INC. | $55.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $52.35 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $51.98 | 2024-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $46.56 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $45.03 | 2019-2024 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $44.20 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $38.34 | 2024 | Opsumit |
| Gilead Sciences, INC. | $30.97 | 2025 | |
| Allergan, INC. | $29.81 | 2019-2020 | |
| Verona Pharma, INC. | $25.70 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $25.20 | 2025 | Inspire |
| Lundbeck LLC | $24.64 | 2024 | Rexulti |
| Scilex Pharmaceuticals INC. | $23.30 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.77 | 2023 | Rexulti |
| Acella Pharmaceuticals, LLC | $15.46 | 2025 | NP Thyroid 60 |
| Amneal Pharmaceuticals LLC | $15.19 | 2024 | Unithroid |
| Teva Pharmaceuticals USA, INC. | $15.17 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $14.82 | 2025 | Neffy |
| Radius Health, INC. | $14.71 | 2024 | Tymlos |
| Sanofi Pasteur INC. | $13.49 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Khandagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.